The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain
Science Signaling · 06.08.2024 · 17 (848)
DOI: 10.1126/scisignal.adk1822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, erschienen am 06.08.2024. Verfasst von Naoto Watamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. Hauptthemen laut MEDLINE: Neprilysin, Dopamine, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Deposition of amyloid-β (Aβ) in the brain can impair neuronal function and contribute to cognitive decline in Alzheimer’s disease (AD). Here, we found that dopamine and the dopamine precursor levodopa (also called l -DOPA) induced Aβ degradation in the brain. Chemogenetic approaches in mice revealed that the activation of dopamine release from ventral tegmental area (VTA) neurons increased the abundance and activity of the Aβ-degrading enzyme neprilysin and reduced the amount of Aβ deposits in the prefrontal cortex in a neprilysin-dependent manner. Aged mice had less dopamine and neprilysin in the anterior cortex, a decrease that was accentuated in AD model mice. Treating AD model mice with levodopa reduced Aβ deposition and improved cognitive function. These observations demonstrate that dopamine promotes brain region–specific, neprilysin-dependent degradation of Aβ, suggesting that dopamine-associated strategies have the potential to treat this aspect of AD pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, 171 64, Solna, Sweden.
- Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
- Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi 464-8601, Japan.
- Department of Genome-based Drug Discovery & Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, 852-8521, Japan.
- Laboratory for Systems Neurophysiology, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
ORCID-Profile: Ryo Fujioka, Naoko Kamano, Per Nilsson, Takashi Saito, Nobuhisa Iwata, Shigeyoshi Fujisawa, Takaomi C Saido
Zitieren
APA
Watamura, N., Kakiya, N., Fujioka, R., Kamano, N., Takahashi, M., Nilsson, P., Saito, T., Iwata, N., Fujisawa, S., & Saido, T. C. (2024). The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain. Science Signaling, 17(848). https://doi.org/10.1126/scisignal.adk1822
Vancouver
Watamura N, Kakiya N, Fujioka R, Kamano N, Takahashi M, Nilsson P, et al. The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain. Science Signaling. 2024;17(848). doi:10.1126/scisignal.adk1822
BibTeX
@article{Watamura2024,
author = {Watamura, Naoto and Kakiya, Naomasa and Fujioka, Ryo and Kamano, Naoko and Takahashi, Mika and Nilsson, Per and Saito, Takashi and Iwata, Nobuhisa and Fujisawa, Shigeyoshi and Saido, Takaomi C},
title = {The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain},
journal = {Science Signaling},
year = {2024},
volume = {17},
number = {848},
doi = {10.1126/scisignal.adk1822}
}
EUVIMED